The FLOW trial, the first dedicated kidney outcomes trial designed specifically to evaluate a GLP-1 medicine in people with chronic kidney disease and type 2 diabetes, was stopped early because an independent monitoring committee determined that clear evidence of benefit had already emerged.[11] In clinical research, trials are rarely stopped early
More and more as we get a little bit more sophisticated, there gets to be more awareness of endometriosis and more women go into radiology, we are coming up with more ways to image patients that will give clues as to the diagnosis
The latest wave of the AMC consumer study shows that 7% of the population has used GLP-1 medications specifically for weight loss
Our wellness IV drips are designed to boost energy, improve immune function, and even alleviate the symptoms of hangovers
As well, treatment with alogliptin (20 mg/kg/day), a selective DPP-4 inhibitor, showed similar anti-inflammatory effects in the injured arteries of low-density lipoprotein receptor-deficient mice [69]